Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > duchenne muscular dystrophy dmd drugs market
Get a free sample of Duchenne Muscular Dystrophy (DMD) Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Duchenne Muscular Dystrophy (DMD) Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Increasing research and development (R&D) funding significantly drives the DMD drugs market by catalyzing innovation and accelerating the development of novel therapies. Expanded funding supports enable pharmaceutical companies and research institutions to explore advanced treatment modalities such as gene therapy, exon skipping, and gene editing technologies.
The corticosteroids segment of the market will account for USD 1.2 billion by 2032, attributed to their well-established efficacy in slowing the progression of the disease.
The duchenne muscular dystrophy drugs market size was valued at USD 3.2 billion in 2023 and is estimated to grow at 11.6% CAGR between 2024 to 2032, driven by increasing burden of DMD and rising demand for novel therapies.
Asia Pacific duchenne muscular dystrophy drugs market held a decent share in 2023 and is poised to grow at 12% CAGR during 2024-2032, driven by increasing awareness and improved diagnostic capabilities.
Aurobindo Pharma, Capricor Therapeutics, Inc, Catalyst Pharmaceuticals Inc, EspeRare Foundation, and FibroGen, Inc. among others.